10-K · March 4, 2026
Sight Sciences reported Q4 2025 revenue of $20.385M and EPS of -$0.08, modestly beating consensus (revenue beat +0.23%, EPS beat). Margins and profitability show a clear trajectory of improvement through 2025 (gross…
Earnings analysis · 10-Q
SGHT earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Sight Sciences, Inc. reported Q1 2026 financials showing a revenue of $19.7 million, exceeding consensus estimates of $18.55 million. However, the diluted EPS of -0.24 missed expectations of -0.20, reflecting ongoing…
Read full summary
Sight Sciences, Inc. reported Q1 2026 financials showing a revenue of $19.7 million, exceeding consensus estimates of $18.55 million. However, the diluted EPS of -0.24 missed expectations of -0.20, reflecting ongoing challenges in profitability. The company indicated strong growth in its Interventional Dry Eye segment, contributing to an overall revenue increase of 12.5% year-over-year.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.24
- Gross margin
- 86.2%
What stood out
-
Revenue Surpass Estimates
Revenue reached $19.7 million, exceeding the estimate of $18.55 million by 6.2%.
-
Strong Interventional Dry Eye Growth
Interventional Dry Eye segment revenue grew to $1.4 million, an increase of 244% compared to the prior year.
-
Improved Gross Margin Stability
Total gross margin was stable at 86.2%, maintaining profitability despite challenges.
-
Reduced R&D Expenses
R&D expenses decreased by 42.5% year-over-year to $2.5 million.
-
Decrease in Operational Losses
Loss from operations improved to $12.4 million, a reduction of 10.4% from the prior year.
-
Increase in Cash Reserves
Cash and cash equivalents increased to $85 million, reflecting stronger liquidity.
What to watch
-
Continuing Operating Loss
Net loss for the quarter was $12.98 million, indicating persistent profitability challenges.
-
High SG&A Expenses
SG&A expenses rose to $26.8 million, driven by $5.4 million in legal expenses from ongoing litigation.
-
Dependency on Third-Party Manufacturers
The reliance on third-party suppliers for components exposes the company to supply chain risks.
Management's outlook
No explicit quantitative guidance provided in the filing.
Earlier filings 4
10-Q · August 7, 2025
Sight Sciences reported Q2 2025 revenue of $19,564,000 and GAAP diluted loss per share of $(0.23). Gross margin remained high at 84.8% while operating loss narrowed modestly to $(11,667,000) for the quarter. Cash…
10-Q · May 8, 2025
Sight Sciences reported Q1 revenue of $17,508,000 (Q1 2024: $19,265,000), with gross margin holding at 86.2% but operating margin deteriorating to -79.2%. Net loss was $14,154,000 (EPS -$0.28), cash and cash equivalents…
10-K · March 7, 2025
Sight Sciences’ 10-K (fiscal year ended December 31, 2024) emphasizes a dual-product strategy: Surgical Glaucoma (OMNI, SION) and Dry Eye (TearCare), with Surgical Glaucoma driving the business (95% of 2024 revenue).…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.